Modelling and analysis of LRRK2 mutations in iPSC-derived dopaminergic neurons and astrocytes

Modelling and analysis of LRRK2 mutations in iPSC-derived dopaminergic neurons and astrocytes

<p>Parkinson's disease (PD) is a common neurodegenerative disorder, characterised by preferential loss of ventral midbrain dopaminergic (vmDA) neurons in the substantia nigra pars compacta (SNc). The majority of PD cases have unknown aetiology; however, between 5-10% arise due to known ge...

Bibliografiset tiedot
Päätekijä:	Booth, H
Muut tekijät:	Wade-Martins, R
Aineistotyyppi:	Opinnäyte
Kieli:	English
Julkaistu:	2017

Samankaltaisia teoksia

Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons
Tekijä: Andrew J. Schwab, et al.
Julkaistu: (2017-12-01)

RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes
Tekijä: Booth, H, et al.
Julkaistu: (2019)

The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson’s disease
Tekijä: Aurelie de Rus Jacquet, et al.
Julkaistu: (2021-09-01)

Ergothioneine-Mediated Neuroprotection of Human iPSC-Derived Dopaminergic Neurons
Tekijä: Damien Meng-Kiat Leow, et al.
Julkaistu: (2024-06-01)

Pro-maturational effects of human iPSC-derived cortical astrocytes upon iPSC-derived cortical neurons
Tekijä: Anne Hedegaard, et al.
Julkaistu: (2020)

RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes
Tekijä: Heather D.E. Booth, et al.
Julkaistu: (2019-09-01)

Establishment of an in vitro model for analyzing mitochondrial ultrastructure in PRKN-mutated patient iPSC-derived dopaminergic neurons
Tekijä: Mutsumi Yokota, et al.
Julkaistu: (2021-03-01)

Studying α-Synuclein pathology using iPSC-derived dopaminergic neurons
Tekijä: Zambon, F
Julkaistu: (2017)

Cytokine Profiling in Human iPSC-Derived Dopaminergic Neuronal and Microglial Cultures
Tekijä: Evelyn Knappe, et al.
Julkaistu: (2023-10-01)

Modeling riboflavin transporter deficiency type 2: from iPSC-derived motoneurons to iPSC-derived astrocytes
Tekijä: Valentina Magliocca, et al.
Julkaistu: (2024-07-01)

Neurite Aggregation and Calcium Dysfunction in iPSC-Derived Sensory Neurons with Parkinson’s Disease-Related LRRK2 G2019S Mutation
Tekijä: Andrew J. Schwab, et al.
Julkaistu: (2015-12-01)

SARS-CoV-2 hampers dopamine production in iPSC-derived dopaminergic neurons
Tekijä: G. Cappelletti, et al.
Julkaistu: (2023-12-01)

Aberrant epigenome in iPSC‐derived dopaminergic neurons from Parkinson's disease patients
Tekijä: Rubén Fernández‐Santiago, et al.
Julkaistu: (2015-10-01)

Detailed Analysis of the Genetic and Epigenetic Signatures of iPSC-Derived Mesodiencephalic Dopaminergic Neurons
Tekijä: Reinhard Roessler, et al.
Julkaistu: (2014-04-01)

Identification of ASCL1 as a determinant for human iPSC-derived dopaminergic neurons
Tekijä: Aaron M. Earley, et al.
Julkaistu: (2021-11-01)

Identification of bioactive metabolites in human iPSC-derived dopaminergic neurons with PARK2 mutation: Altered mitochondrial and energy metabolism
Tekijä: Okarmus, J, et al.
Julkaistu: (2021)

Mitochondrial Phenotypes in Parkinson’s Diseases—A Focus on Human iPSC-Derived Dopaminergic Neurons
Tekijä: Leonie M. Heger, et al.
Julkaistu: (2021-12-01)

Mitochondrial Dysregulation and Impaired Autophagy in iPSC-Derived Dopaminergic Neurons of Multiple System Atrophy
Tekijä: Giacomo Monzio Compagnoni, et al.
Julkaistu: (2018-11-01)

Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation
Tekijä: Joanna A. Korecka, et al.
Julkaistu: (2019-01-01)

Mutated LRRK2 induces a reactive phenotype and alters migration in human iPSC-derived pericyte-like cells
Tekijä: Sanni Peltonen, et al.
Julkaistu: (2024-11-01)

Induced pluripotent stem cell (iPSC)-derived dopaminergic models of Parkinson's disease.
Tekijä: Beevers, J, et al.
Julkaistu: (2013)

Glutamate-glutamine homeostasis is perturbed in neurons and astrocytes derived from patient iPSC models of frontotemporal dementia
Tekijä: Blanca I. Aldana, et al.
Julkaistu: (2020-09-01)

Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools
Tekijä: Kenshiro Fujise, et al.
Julkaistu: (2025-01-01)

Comparison of two protocols for the generation of iPSC-derived human astrocytes
Tekijä: Patrycja Mulica, et al.
Julkaistu: (2023-09-01)

The multifaceted role of LRRK2 in Parkinson's disease: From human iPSC to organoids
Tekijä: Asmaa Oun, et al.
Julkaistu: (2022-10-01)

LRRK2 Kinase Inhibition Rescues Deficits in Lysosome Function Due to Heterozygous GBA1 Expression in Human iPSC-Derived Neurons
Tekijä: Anwesha Sanyal, et al.
Julkaistu: (2020-05-01)

Patient iPSC-Derived Neurons for Disease Modeling of Frontotemporal Dementia with Mutation in CHMP2B
Tekijä: Yu Zhang, et al.
Julkaistu: (2017-03-01)

Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia
Tekijä: Reina Bassil, et al.
Julkaistu: (2021-09-01)

A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides
Tekijä: Kimberly C. Paul, et al.
Julkaistu: (2023-05-01)

Targeting TFEB and TFE3 in iPSC-derived dopaminergic neurons to correct autophagic/lysosomal deficits in Parkinson's disease
Tekijä: McGuinness, W
Julkaistu: (2023)

Chinese medicine PaBing-II protects human iPSC-derived dopaminergic neurons from oxidative stress
Tekijä: Shouhai Wu, et al.
Julkaistu: (2024-08-01)

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction
Tekijä: Laurie H. Sanders, et al.
Julkaistu: (2014-02-01)

iPSC-derived reactive astrocytes from patients with multiple sclerosis protect cocultured neurons in inflammatory conditions
Tekijä: Janis Kerkering, et al.
Julkaistu: (2023-07-01)

Intracellular deposits of amyloid-beta influence the ability of human iPSC-derived astrocytes to support neuronal function
Tekijä: Evangelos Konstantinidis, et al.
Julkaistu: (2023-01-01)

PARK2 mutation causes metabolic disturbances and impaired survival of human iPSC-derived neurons
Tekijä: Bogetofte, H, et al.
Julkaistu: (2019)

Generation of gene-corrected iPSC line, KIOMi002-A, from Parkinson's disease patient iPSC with LRRK2 G2019S mutation using BAC-based homologous recombination
Tekijä: Seo-Young Lee, et al.
Julkaistu: (2019-12-01)

Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson’s disease related transcriptional profile and function
Tekijä: Sohvi Ohtonen, et al.
Julkaistu: (2023-12-01)

Synergic action of L-acetylcarnitine and L-methylfolate in Mouse Models of Stress-Related Disorders and Human iPSC-Derived Dopaminergic Neurons
Tekijä: Rosamaria Orlando, et al.
Julkaistu: (2022-06-01)

CRISPRi: a way to integrate iPSC-derived neuronal models
Tekijä: Franks, SNJ, et al.
Julkaistu: (2024)

Using Human iPSC-Derived Neurons to Model TAU Aggregation.
Tekijä: An Verheyen, et al.
Julkaistu: (2015-01-01)